Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 17:55
04/06/21
04/06
17:55
04/06/21
17:55
SGH

Smart Global

$48.71 /

-0.76 (-1.54%)

, NVST

Envista

$40.91 /

-0.82 (-1.97%)

, IDCC

InterDigital

$65.99 /

+0.35 (+0.53%)

, QGEN

Qiagen

$50.00 /

+0.345 (+0.69%)

, MAXN

Maxeon Solar

$28.43 /

-1.76 (-5.83%)

, FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

, FIXX

Homology Medicines

$9.30 /

-0.34 (-3.53%)

, PHR

Phreesia

$55.13 /

-0.005 (-0.01%)

, IONS

Ionis Pharmaceuticals

$47.25 /

+0.35 (+0.75%)

, LI

Li Auto

$25.52 /

+0.55 (+2.20%)

, OM

Outset Medical

$58.04 /

+1.21 (+2.13%)

Check out this evening's…

ShowHide Related Items >><<
SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

OM Outset Medical
$58.04 /

+1.21 (+2.13%)

NVST Envista
$40.91 /

-0.82 (-1.97%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IDCC InterDigital
$65.99 /

+0.35 (+0.53%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

SGH Smart Global
$48.71 /

-0.76 (-1.54%)

02/10/21 Stifel
Smart Global price target raised to $55 from $48 at Stifel
01/06/21 Needham
Smart Global price target raised to $56 from $39 at Needham
01/06/21 Deutsche Bank
Smart Global price target raised to $48 from $44 at Deutsche Bank
01/04/21 Deutsche Bank
Smart Global price target raised to $44 from $35 at Deutsche Bank
NVST Envista
$40.91 /

-0.82 (-1.97%)

02/11/21 Piper Sandler
Envista price target raised to $41 from $28 at Piper Sandler
01/08/21 Credit Suisse
Envista upgraded to Outperform from Neutral at Credit Suisse
10/30/20 JPMorgan
Envista price target raised to $30 from $28 at JPMorgan
10/30/20 Piper Sandler
Envista price target raised to $28 from $22 at Piper Sandler
IDCC InterDigital
$65.99 /

+0.35 (+0.53%)

03/18/21 B. Riley
B. Riley keeps Buy on InterDigital, still sees renewal opportunity with LG
02/19/21 B. Riley
InterDigital price target raised to $123 from $100 at B. Riley Securities
10/08/20 B. Riley
InterDigital settlement with Lenovo now more likely, says B. Riley Securities
08/27/20 B. Riley
U.K. Supreme Court ruling positive for InterDigital, says B. Riley FBR
QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/19/21 Roth Capital
Maxeon Solar initiated with a Buy at Roth Capital
01/04/21 Goldman Sachs
Maxeon Solar price target raised to $18 from $15 at Goldman Sachs
11/10/20 Raymond James
Maxeon Solar upgraded to Outperform at Raymond James on Biden election
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

03/31/21 BofA
BofA upgrades FibroGen to Buy, sees roxadustat approval being 'most likely'
03/31/21 BofA
FibroGen upgraded to Buy from Neutral at BofA
03/02/21
Fly Intel: Top five analyst downgrades
03/02/21 Jefferies
FibroGen downgraded to Hold at Jefferies on increased risk for roxadustat
FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
PHR Phreesia
$55.13 /

-0.005 (-0.01%)

04/01/21 SVB Leerink
Phreesia price target lowered to $75 from $85 at SVB Leerink
04/01/21 Baird
Phreesia initiated with an Outperform at Baird
03/31/21 Piper Sandler
Phreesia price target raised to $58 from $56 at Piper Sandler
03/31/21 KeyBanc
Phreesia price target lowered to $70 from $80 at KeyBanc
IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
LI Li Auto
$25.52 /

+0.55 (+2.20%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 Needham
Li Auto initiated with a Buy at Needham
03/11/21 Needham
Li Auto initiated with a Buy at Needham
03/03/21 Wedbush
China growth story worth at least $100/share in bull case to Tesla, says Wedbush
OM Outset Medical
$58.04 /

+1.21 (+2.13%)

12/15/20 Oppenheimer
Oppenheimer starts Outset Medical at Perform, citing competition
12/15/20 Oppenheimer
Outset Medical initiated with a Perform at Oppenheimer
10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

OM Outset Medical
$58.04 /

+1.21 (+2.13%)

NVST Envista
$40.91 /

-0.82 (-1.97%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

IDCC InterDigital
$65.99 /

+0.35 (+0.53%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

  • 09
    Apr
  • 07
    Apr
  • 08
    Apr
  • 08
    Jan
  • 04
    Dec
  • 03
    Dec
  • 21
    Oct
  • 15
    Sep
  • 30
    Jul
QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

OM Outset Medical
$58.04 /

+1.21 (+2.13%)

NVST Envista
$40.91 /

-0.82 (-1.97%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

SGH Smart Global
$48.71 /

-0.76 (-1.54%)

QGEN Qiagen
$50.00 /

+0.345 (+0.69%)

PHR Phreesia
$55.13 /

-0.005 (-0.01%)

MAXN Maxeon Solar
$28.43 /

-1.76 (-5.83%)

LI Li Auto
$25.52 /

+0.55 (+2.20%)

IONS Ionis Pharmaceuticals
$47.25 /

+0.35 (+0.75%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Hot Stocks
Qiagen launches QIAseq DIRECT SARS-CoV-2 Kit » 16:08
04/06/21
04/06
16:08
04/06/21
16:08
QGEN

Qiagen

$49.90 /

+0.25 (+0.50%)

The company states:…

The company states: "QIAGEN announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly reduces library turnaround times and plastics use compared with ARTIC project protocols. The lab and bioinformatic protocols of the ARTIC network, an initiative funded by the Wellcome Trust, are considered the gold standard in NGS-based characterization of SARS-CoV-2 genomes. High-throughput NGS is increasingly being used to conduct genomic surveillance and research on new and potentially dangerous COVID-19 variants that continue to emerge. These viral mutations have become an area of intense concern particularly with regard to vaccine efficacy. As a result, sequencing laboratories worldwide have come under intense pressure to provide results as quickly as possible. QIAseq DIRECT SARS-CoV-2 supports sample multiplexing with up to 768 Dual Molecular Indices - unique markers tagged to molecules in a sample to eliminate errors from downstream analysis - in a library preparation workflow from extracted viral RNA that reduces turnaround time to as little as four hours. This also increases the amount of samples per sequencer to over 6,000 samples on the highest-throughput instruments. The kit also cuts plastics usage by 50%, drastically reduces hands-on time, requires no fragmentation or ligation reactions and can be readily automated with robotic liquid handlers. The viral enrichment approach delivers superior uniformity of coverage across the SARS-CoV-2 genome as well as deeper sequencing performance compared with the most widely used amplicon-based options."

ShowHide Related Items >><<
QGEN Qiagen
$49.90 /

+0.25 (+0.50%)

QGEN Qiagen
$49.90 /

+0.25 (+0.50%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
QGEN Qiagen
$49.90 /

+0.25 (+0.50%)

QGEN Qiagen
$49.90 /

+0.25 (+0.50%)

QGEN Qiagen
$49.90 /

+0.25 (+0.50%)

QGEN Qiagen
$49.90 /

+0.25 (+0.50%)

Over a week ago
Conference/Events
Hanson Wade to hold a virtual conference » 04:55
04/01/21
04/01
04:55
04/01/21
04:55
BIIB

Biogen

$280.05 /

+4.17 (+1.51%)

, PFE

Pfizer

$36.24 /

+0.13 (+0.36%)

, RARE

Ultragenyx

$114.03 /

+2.24 (+2.00%)

, FOLD

Amicus

$9.89 /

+0.49 (+5.21%)

, ORTX

Orchard Therapeutics

$7.23 /

+0.07 (+0.98%)

, QGEN

Qiagen

$48.73 /

+0.765 (+1.60%)

Gene Therapy…

Gene Therapy Comparabililty Virtual Conference will be held on March 31-April 1.

ShowHide Related Items >><<
RARE Ultragenyx
$114.03 /

+2.24 (+2.00%)

QGEN Qiagen
$48.73 /

+0.765 (+1.60%)

PFE Pfizer
$36.24 /

+0.13 (+0.36%)

ORTX Orchard Therapeutics
$7.23 /

+0.07 (+0.98%)

FOLD Amicus
$9.89 /

+0.49 (+5.21%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/25/21 Mizuho
Two 'low probability' Biogen events could drive upside, says Mizuho
03/23/21 Piper Sandler
Neurologist survey shows erosion for Biogen franchises, says Piper Sandler
02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
PFE Pfizer
$36.24 /

+0.13 (+0.36%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
RARE Ultragenyx
$114.03 /

+2.24 (+2.00%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
FOLD Amicus
$9.89 /

+0.49 (+5.21%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
ORTX Orchard Therapeutics
$7.23 /

+0.07 (+0.98%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
QGEN Qiagen
$48.73 /

+0.765 (+1.60%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
RARE Ultragenyx
$114.03 /

+2.24 (+2.00%)

QGEN Qiagen
$48.73 /

+0.765 (+1.60%)

PFE Pfizer
$36.24 /

+0.13 (+0.36%)

ORTX Orchard Therapeutics
$7.23 /

+0.07 (+0.98%)

FOLD Amicus
$9.89 /

+0.49 (+5.21%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

  • 29
    Oct
QGEN Qiagen
$48.73 /

+0.765 (+1.60%)

PFE Pfizer
$36.24 /

+0.13 (+0.36%)

FOLD Amicus
$9.89 /

+0.49 (+5.21%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

QGEN Qiagen
$48.73 /

+0.765 (+1.60%)

PFE Pfizer
$36.24 /

+0.13 (+0.36%)

FOLD Amicus
$9.89 /

+0.49 (+5.21%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

QGEN Qiagen
$48.73 /

+0.765 (+1.60%)

PFE Pfizer
$36.24 /

+0.13 (+0.36%)

FOLD Amicus
$9.89 /

+0.49 (+5.21%)

BIIB Biogen
$280.05 /

+4.17 (+1.51%)

Conference/Events
Hanson Wade to hold a virtual conference » 10:37
03/31/21
03/31
10:37
03/31/21
10:37
BIIB

Biogen

$277.54 /

+1.66 (+0.60%)

, PFE

Pfizer

$36.18 /

+0.065 (+0.18%)

, RARE

Ultragenyx

$114.14 /

+2.35 (+2.10%)

, FOLD

Amicus

$9.68 /

+0.28 (+2.98%)

, ORTX

Orchard Therapeutics

$7.24 /

+0.08 (+1.12%)

, QGEN

Qiagen

$48.43 /

+0.47 (+0.98%)

Gene Therapy…

Gene Therapy Comparabililty Virtual Conference will be held on March 31-April 1.

ShowHide Related Items >><<
RARE Ultragenyx
$114.14 /

+2.35 (+2.10%)

QGEN Qiagen
$48.43 /

+0.47 (+0.98%)

PFE Pfizer
$36.18 /

+0.065 (+0.18%)

ORTX Orchard Therapeutics
$7.24 /

+0.08 (+1.12%)

FOLD Amicus
$9.68 /

+0.28 (+2.98%)

BIIB Biogen
$277.54 /

+1.66 (+0.60%)

BIIB Biogen
$277.54 /

+1.66 (+0.60%)

03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/25/21 Mizuho
Two 'low probability' Biogen events could drive upside, says Mizuho
03/23/21 Piper Sandler
Neurologist survey shows erosion for Biogen franchises, says Piper Sandler
02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
PFE Pfizer
$36.18 /

+0.065 (+0.18%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
RARE Ultragenyx
$114.14 /

+2.35 (+2.10%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
FOLD Amicus
$9.68 /

+0.28 (+2.98%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
ORTX Orchard Therapeutics
$7.24 /

+0.08 (+1.12%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
QGEN Qiagen
$48.43 /

+0.47 (+0.98%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
RARE Ultragenyx
$114.14 /

+2.35 (+2.10%)

QGEN Qiagen
$48.43 /

+0.47 (+0.98%)

PFE Pfizer
$36.18 /

+0.065 (+0.18%)

ORTX Orchard Therapeutics
$7.24 /

+0.08 (+1.12%)

FOLD Amicus
$9.68 /

+0.28 (+2.98%)

BIIB Biogen
$277.54 /

+1.66 (+0.60%)

  • 29
    Oct
QGEN Qiagen
$48.43 /

+0.47 (+0.98%)

PFE Pfizer
$36.18 /

+0.065 (+0.18%)

FOLD Amicus
$9.68 /

+0.28 (+2.98%)

BIIB Biogen
$277.54 /

+1.66 (+0.60%)

QGEN Qiagen
$48.43 /

+0.47 (+0.98%)

PFE Pfizer
$36.18 /

+0.065 (+0.18%)

FOLD Amicus
$9.68 /

+0.28 (+2.98%)

BIIB Biogen
$277.54 /

+1.66 (+0.60%)

QGEN Qiagen
$48.43 /

+0.47 (+0.98%)

PFE Pfizer
$36.18 /

+0.065 (+0.18%)

FOLD Amicus
$9.68 /

+0.28 (+2.98%)

BIIB Biogen
$277.54 /

+1.66 (+0.60%)

Recommendations
GN Store Nord price target raised to DKK 550 from DKK 536 at JPMorgan » 12:20
03/29/21
03/29
12:20
03/29/21
12:20
GNNDY

GN Store Nord

$0.00 /

+ (+0.00%)

JPMorgan analyst David…

JPMorgan analyst David Adlington raised the firm's price target on GN Store Nord to DKK 550 from DKK 536 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
GNNDY GN Store Nord
$0.00 /

+ (+0.00%)

02/12/21 JPMorgan
GN Store Nord price target raised to DKK 536 from DKK 455 at JPMorgan
12/09/20 Morgan Stanley
GN Store Nord upgraded to Overweight from Underweight at Morgan Stanley
10/12/20 Credit Suisse
GN Store Nord price target raised to DKK 560 from DKK 465 at Credit Suisse
10/08/20 Citi
GN Store Nord initiated with a Buy at Citi
Hot Stocks
Qiagen receives Emergency Use Authorization for NeuMoDx multiplex test » 05:32
03/29/21
03/29
05:32
03/29/21
05:32
QGEN

Qiagen

$49.27 /

+0.15 (+0.31%)

Qiagen announced the…

Qiagen announced the Emergency Use Authorization by the FDA for the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help healthcare professionals identify and differentiate individuals suspected by a healthcare provider of respiratory viral infection consistent with COVID-19.

ShowHide Related Items >><<
QGEN Qiagen
$49.27 /

+0.15 (+0.31%)

QGEN Qiagen
$49.27 /

+0.15 (+0.31%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
QGEN Qiagen
$49.27 /

+0.15 (+0.31%)

QGEN Qiagen
$49.27 /

+0.15 (+0.31%)

QGEN Qiagen
$49.27 /

+0.15 (+0.31%)

QGEN Qiagen
$49.27 /

+0.15 (+0.31%)

Upgrade
Siemens Healthineers upgraded to Buy from Hold at HSBC » 06:21
03/16/21
03/16
06:21
03/16/21
06:21
SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

HSBC analyst Sezgi…

HSBC analyst Sezgi Oezener upgraded Siemens Healthineers to Buy from Hold with a price target of EUR 53, up from EUR 43. Freshly secured financing and the Varian integration are game-changers warranting a reassessment of the investment case, Oezener tells investors in a research note. The analyst believes Varian will open a new chapter to a more holistic healthcare offering, while the underlying business is also looking brighter.

ShowHide Related Items >><<
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

02/23/21 UBS
Siemens Healthineers price target raised to EUR 46 from EUR 40 at UBS
02/08/21 Berenberg
Siemens Healthineers price target raised to EUR 55 from EUR 54 at Berenberg
02/08/21 Deutsche Bank
Siemens Healthineers price target raised to EUR 46 from EUR 43 at Deutsche Bank
01/27/21 Credit Suisse
Siemens Healthineers price target raised to EUR 48 from EUR 44 at Credit Suisse
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

Over a month ago
Hot Stocks
Quidel slips, drags on peers as demand for testing 'softens significantly' » 14:46
03/10/21
03/10
14:46
03/10/21
14:46
QDEL

Quidel

$130.00 /

-25.51 (-16.40%)

, QGEN

Qiagen

$45.74 /

-1.915 (-4.02%)

, FLGT

Fulgent Genetics

$97.95 /

-12.01 (-10.92%)

, GNMK

GenMark

$16.62 /

-3.3 (-16.57%)

, PKI

PerkinElmer

$120.59 /

-5.41 (-4.29%)

, BDX

Becton Dickinson

$236.90 /

-6.13 (-2.52%)

, HOLX

Hologic

$68.01 /

-3.89 (-5.41%)

Shares of Quidel (QDEL)…

Shares of Quidel (QDEL) are under pressure on Wednesday after the company said demand for testing was down 30%-40% quarter-to-date versus the fourth quarter and that it sees quarterly revenue of "at least" $450M, with consensus estimates at roughly $755M. The guidance also sent shares of several peers, including Qiagen (QGEN) and Fulgent Genetics (FLGT), into negative territory. DEMAND DOWN: During Barclays' Global Health Virtual Conference, Quidel said that testing in February and March has "softened significantly," with demand for testing down 30%-40% quarter-to-date versus the fourth quarter. The company also noted that it sees revenue of "at least" $450M for the quarter, with consensus at $755.07M. For the current fiscal year, Quidel sees revenue of roughly $2.5B, with consensus at $2.87B. PRICE ACTION: In afternoon trading, shares of Quidel have dropped over 16% to $130.75. Also lower, Qiagen has slipped almost 4% to $45.84, Fulgent Genetics has plunged over 12% to $96.09, GenMark (GNMK) has slid more than 18% to $16.31, PerkinElmer (PKI) has slipped over 4% to $120.57, Becton Dickinson (BDX) has slid about 2% to $237.50, and Opko Health (OPKO) and Hologic (HOLX) have dropped about 5% apiece to $4.31 and $68.47, respectively.

ShowHide Related Items >><<
QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

02/19/21 JPMorgan
Quidel price target lowered to $170 from $175 at JPMorgan
02/19/21 Piper Sandler
Quidel should be bought on QuickVue OTC delay, says Piper Sandler
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

03/05/21 Piper Sandler
Fulgent Genetics price target raised to $140 from $135 at Piper Sandler
02/03/21 Piper Sandler
Fulgent Genetics price target raised to $135 from $100 at Piper Sandler
02/01/21 Oppenheimer
Fulgent Genetics price target raised to $130 from $75 at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
GNMK GenMark
$16.62 /

-3.3 (-16.57%)

02/16/21 Canaccord
GenMark price target raised to $24 from $22 at Canaccord
10/09/20 Canaccord
Execution positions GenMark for long-term success, says Canaccord
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
08/05/20 Canaccord
GenMark price target raised to $22 from $20 at Canaccord
PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

02/12/21 Wells Fargo
Wells Fargo sees only 'small chance' of positive FDA panel for Becton
02/05/21 Citi
Becton Dickinson price target raised to $280 from $273 at Citi
02/04/21 Piper Sandler
Becton Dickinson price target raised to $280 from $275 at Piper Sandler
12/15/20
Fly Intel: Top five analyst downgrades
HOLX Hologic
$68.01 /

-3.89 (-5.41%)

02/22/21 BTIG
Hologic price target raised to $91 from $84 at BTIG
01/28/21 Wells Fargo
Hologic price target raised to $95 from $90 at Wells Fargo
12/08/20 Argus
Hologic price target raised to $100 from $85 at Argus
11/20/20
Fly Intel: Top five analyst downgrades
QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

  • 21
    May
  • 07
    May
QDEL Quidel
$130.00 /

-25.51 (-16.40%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

QDEL Quidel
$130.00 /

-25.51 (-16.40%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

GNMK GenMark
$16.62 /

-3.3 (-16.57%)

FLGT Fulgent Genetics
$97.95 /

-12.01 (-10.92%)

BDX Becton Dickinson
$236.90 /

-6.13 (-2.52%)

QGEN Qiagen
$45.74 /

-1.915 (-4.02%)

PKI PerkinElmer
$120.59 /

-5.41 (-4.29%)

HOLX Hologic
$68.01 /

-3.89 (-5.41%)

Hot Stocks
Qiagen launches QIAsphere cloud-based platform » 16:12
03/03/21
03/03
16:12
03/03/21
16:12
QGEN

Qiagen

$49.12 /

-1.34 (-2.66%)

Qiagen has launched its…

Qiagen has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week. "The launch of QIAsphere platform for QIAstat-Dx is a key step in syndromic testing, but above all for our customers: it is our commitment to make their life easier, their testing workflow more manageable and our interactions faster," said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. "Digital diagnostics sets a new paradigm in syndromic testing. It addresses the growing need of bringing molecular PCR COVID testing closer to patients and to decentralized environments such as ICUs, emergency rooms or satellite labs."

ShowHide Related Items >><<
QGEN Qiagen
$49.12 /

-1.34 (-2.66%)

QGEN Qiagen
$49.12 /

-1.34 (-2.66%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
QGEN Qiagen
$49.12 /

-1.34 (-2.66%)

QGEN Qiagen
$49.12 /

-1.34 (-2.66%)

QGEN Qiagen
$49.12 /

-1.34 (-2.66%)

QGEN Qiagen
$49.12 /

-1.34 (-2.66%)

Conference/Events
The Genome Partnership to hold a virtual meeting » 04:55
03/03/21
03/03
04:55
03/03/21
04:55
NSTG

NanoString

$74.34 /

-0.15 (-0.20%)

, TWST

Twist Bioscience

$141.72 /

-3.31 (-2.28%)

, PACB

Pacific Biosciences

$34.32 /

-0.925 (-2.62%)

, QGEN

Qiagen

$50.49 /

+0.14 (+0.28%)

, TXG

10x Genomics

$186.77 /

-0.02 (-0.01%)

, CDXS

Codexis

$22.59 /

-0.81 (-3.46%)

, PKI

PerkinElmer

$127.46 /

-2.31 (-1.78%)

, ILMN

Illumina

$441.51 /

-4.8 (-1.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BNGO

Bionano Genomics

$9.47 /

-0.37 (-3.76%)

Advances in Genome…

Advances in Genome Biology & Technology: AGBT 2021 Virtual Meeting will be held on March 1-3. Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

CDXS Codexis
$22.59 /

-0.81 (-3.46%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

03/02/21 JPMorgan
NanoString price target raised to $80 from $75 at JPMorgan
03/02/21 Baird
NanoString price target raised to $78 from $70 at Baird
01/11/21 Baird
NanoString price target raised to $70 from $60 at Baird
01/06/21 Cowen
NanoString upgraded to Outperform with $75 target at Cowen
TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
02/05/21 JPMorgan
Twist Bioscience downgraded to Underweight from Neutral at JPMorgan
01/04/21 Evercore ISI
Evercore ISI cuts Twist Bioscience to In Line, says new verticals take time
01/04/21 Evercore ISI
Twist Bioscience downgraded to In Line from Outperform at Evercore ISI
PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

02/11/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald
02/11/21 Piper Sandler
Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler
01/15/21 Piper Sandler
Pacific Biosciences price target raised to $20 from $12 at Piper Sandler
01/12/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald
QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
02/18/21 Citi
10x Genomics price target raised to $240 from $195 at Citi
12/16/20 Citi
10x Genomics price target raised to $195 from $165 at Citi
CDXS Codexis
$22.59 /

-0.81 (-3.46%)

03/01/21 Stifel
Codexis initiated with a Buy at Stifel
12/30/20 Benchmark
Codexis price target raised to $29 from $21 at Benchmark
07/15/20 Stephens
Codexis resumed with an Overweight at Stephens
03/10/20 Benchmark
Codexis initiated with a Buy at Benchmark
PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
ILMN Illumina
$441.51 /

-4.8 (-1.08%)

03/02/21 Barclays
Illumina started with an Underweight at Barclays on near-term growth issues
03/02/21 Barclays
Illumina initiated with an Underweight at Barclays
02/16/21 BTIG
Illumina price target raised to $570 from $410 at BTIG
02/12/21 Piper Sandler
Illumina price target raised to $510 from $415 at Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
02/24/21 Morgan Stanley
Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/17/21 UBS
UBS downgrades Roche to Neutral on risk to 2022 estimates
BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

CDXS Codexis
$22.59 /

-0.81 (-3.46%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

  • 20
    Jan
  • 08
    Jan
  • 03
    Dec
  • 03
    Dec
  • 11
    Nov
  • 08
    Oct
  • 11
    Sep
  • 12
    Aug
  • 04
    Jun
RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

TXG 10x Genomics
$186.77 /

-0.02 (-0.01%)

TWST Twist Bioscience
$141.72 /

-3.31 (-2.28%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

NSTG NanoString
$74.34 /

-0.15 (-0.20%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

CDXS Codexis
$22.59 /

-0.81 (-3.46%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

QGEN Qiagen
$50.49 /

+0.14 (+0.28%)

PKI PerkinElmer
$127.46 /

-2.31 (-1.78%)

PACB Pacific Biosciences
$34.32 /

-0.925 (-2.62%)

ILMN Illumina
$441.51 /

-4.8 (-1.08%)

BNGO Bionano Genomics
$9.47 /

-0.37 (-3.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.